Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Novartis is a leading global pharmaceutical company headquartered in Basel, Switzerland (CH). The company researches, develops, and distributes innovative medicines and therapies. Through scientific excellence in areas like oncology and gene therapy, Novartis improves patient health worldwide, offering groundbreaking healthcare solutions for a better quality of life.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Novartis (NOT) reported its Q2 2026 financial results on July 21, 2026, before market open. The company reported earnings per share (EPS) of 1.95 CHF, beating the analyst estimate of 1.76 CHF by 11.2%. Quarterly revenue reached 11,664 million CHF. Following the announcement, the stock price rose by 1.98%.
Generated automatically from our data — as of 07/29/2026 Read the article →
Novartis is scheduled to report its next quarterly earnings on 10/27/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Novartis last reported quarterly earnings on 7/21/2026 (Q2 2026). Earnings per share (EPS) came in at 1.95 CHF.
Novartis has beaten analyst EPS estimates in 2 of its last 3 evaluated quarters (beat rate: 66.7%).
For fiscal year 2025, Novartis paid a dividend of 3.70 CHF per share.
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: 3 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.
| Fiscal year | Dividend per share | Ex-date | Payment date |
|---|---|---|---|
| 2025 | 3.70 CHF | 3/10/2026 | 3/12/2026 |
| 2024 | 3.50 CHF | – | – |
| 2023 | 3.30 CHF | – | – |
| 2022 | 3.20 CHF | – | – |
| 2021 | 3.10 CHF | – | – |
| 2020 | 3.00 CHF | – | – |
| 2019 | 2.95 CHF | – | – |
| 2018 | 2.85 CHF | – | – |
| 2017 | 2.80 CHF | – | – |
| 2016 | 2.75 CHF | – | – |
| 2015 | 2.70 CHF | – | – |
| 2014 | 2.60 CHF | – | – |
… and 17 more fiscal years
Source: Novartis investor relations, 29 fiscal years.
Past dividends are no guarantee of future payouts.